PE-22-28

Summary

PE 22-28 is a 7-amino-acid peptide designed from the degradation products of spadin, a sortilin-derived peptide that blocks the TREK-1 potassium channel; it blocked human TREK-1 far more potently than spadin (IC50 0.12 nM against 40-60 nM). · pmid:28955242

Mechanism

In mouse models of depression, PE 22-28 and its derivatives reduced immobility and feeding latency and induced neurogenesis after four days of treatment. · pmid:28955242

Identity

PubChem CID 165437303: L-Arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl-, C35H55N11O9, 773.9 g/mol. · pubchem:165437303

CAS registry number 1801959-12-5. · pubchem:165437303

IUPAC name: (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid. · pubchem:165437303

Where the evidence actually sits

Proportion of the 1 claim about PE-22-28 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for PE-22-28 yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

1. Approved-label dose · a resolved regulatory document names a labelled dose

   nothing resolved on this rung

2. Studied human doses · resolved human studies at the established tier

   nothing resolved on this rung

3. Observational evidence · resolved human data at the emerging tier: thin, or contested

   nothing resolved on this rung

4. Community-reported protocols · protocol propositions from distinct members, counted once per human

   nothing resolved on this rung

5. Preclinical evidence · resolved animal, cell or mechanistic work
   • Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. · pmid 28955242 · 2017

1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.